Russian plans to establish production of orphan drugs

2 September 2019

The Russian government has announced its plans to increase state funding for the purchases of orphan drugs and create conditions for the beginning of their production within the country, according to recent statements from the state press-service, reports The Pharma Letter’s local correspondent.

For this purpose, the list of diseases that are treated by such drugs will be significantly expanded. In addition, the government plans to increase the number of patients that will receive such drugs.

According to estimates of the Russian Ministry of Health, the number of patients that suffer from orphan diseases in the country is in the range of 1-1.5 million people.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK